At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial
proceedings of the national academy of sciences
And by educating patients on both the benefits and risks, we can help them become more alert and attuned to their GI symptoms even before they start this medication. Advertisement Advertisement A new study shows that an AI-enabled bundled system of sensors and coaching reduced A1C with fewer medications TRANSITION-T2D RCT results for patients with T2D receiving MDI Large retrospective analysis may prompt prospective studies Robust signal from observational study raises prospect of a long-sought medical therapy Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Emerging evidence suggests a patient-specific approach Looking at the real-world impact and the future pipeline of targeted therapies
Learn more Thymosin Alpha-1 Peptide Therapy Thymosin Alpha-1 is a thymus-derived immune-modulating peptide studied for its support of T-cell maturation and natural killer cell activity, offered under physician supervision
Contrave combines opioid antagonism with norepinephrine/dopamine reuptake inhibition
However, both come with serious health and legal risks
